Please assess the completion status of the following clinical trial:

Trial Title: Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years;~* American Society of Anesthesiologists (ASA) physical status 1-3;~* Scheduled for catheter-based neurointerventional procedures including coiling and stent insertion;~* General anesthesia.~Exclusion Criteria:~* Suspected difficult intubation;~* Neuromuscular disorder;~* Renal impairment creatinine ≥ 2 mg /dl;~* Hepatic dysfunction;~* History of malignant hyperthermia;~* Allergy to neuromuscular blocking drugs, Sugammadex, neostigmine or glycopyrrolate;~* Perioperative respiratory infections and/or pneumonia;~* Intubated or unresponsive;~* Pregnancy or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neostigmine with glycopyrrolate (Type: ACTIVE_COMPARATOR): Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
- Sugammadex (Type: EXPERIMENTAL): Sugammadex 4 mg/kg at the end surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).